MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Recruiting · NCT06050707 · Interventional (participants receive a specific treatment) · Lead sponsor: University Health Network, Toronto
View the official record on ClinicalTrials.gov →Interventions studied
Radiotherapy - High risk groupRadiotherapy - Intermediate risk groupRadiotherapy - Low risk groupRadiotherapy - Standard risk group
What this trial is about
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with pathologically proven diagnosis of anal SCC. This may include tumors of non-keratinizing histology such as basoloid or cloacogenic histology. Individuals with squamous cell carcinoma of the anal margin are eligible.
- Clinical stage T1-4 N0-1 M0 (the Union for International Cancer Control (UICC) / the American Joint Committee on Cancer (AJCC) 8th Ed)
- Patients must be eligible for definitive RT or CRT
- Must be ≥ 18 years of age
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Exclusion criteria
- Previous chemotherapy, RT or curative-intent surgical treatment (i.e. APR) for anal cancer.
- Any previous RT to the abdomino-pelvic region that would result in overlap of RT volume for the current study.
- Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
Where it is running
5 locations listed across 2 US states.
- Allegheny Health Network - Pittsburgh, Pennsylvania, United States
- Medical College of Wisconsin Cancer Center - Milwaukee, Wisconsin, United States
- Princess Margaret Cancer Centre - Toronto, Ontario, Canada
- CHUM - Centre hospitalier de l'Université de Montréal - Montreal, Quebec, Canada
- Austin Health - Heidelberg, Victoria, Australia